Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis
Abstract Background Postpartum depression (PPD) is categorized by the Disorders-Fifth Edition as depression that begins during pregnancy or within the first month after giving birth. Ketamine and esketamine have shown promising results in the treatment of several depressive disorders, which suggests...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Pregnancy and Childbirth |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12884-025-07186-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861512538685440 |
|---|---|
| author | Moaz Yasser Darwish Abdallah A. Helal Yousif Ahmed Othman Manar Alaa Mabrouk Aya Alrawi Taha Abd-ElSalam Ashraf Nada K. Abdelsattar Fatma Mohammed Sayed Mohamed Abd-ElGawad |
| author_facet | Moaz Yasser Darwish Abdallah A. Helal Yousif Ahmed Othman Manar Alaa Mabrouk Aya Alrawi Taha Abd-ElSalam Ashraf Nada K. Abdelsattar Fatma Mohammed Sayed Mohamed Abd-ElGawad |
| author_sort | Moaz Yasser Darwish |
| collection | DOAJ |
| description | Abstract Background Postpartum depression (PPD) is categorized by the Disorders-Fifth Edition as depression that begins during pregnancy or within the first month after giving birth. Ketamine and esketamine have shown promising results in the treatment of several depressive disorders, which suggests that they may have a role in the prevention of PPD. This systematic review and meta-analysis aim to update evidence about the efficacy and safety of using ketamine and esketamine to reduce PPD incidence. Methods We searched four databases, PubMed, Scopus, Web of Science, and Cochrane, to collect relevant studies. We included studies which investigated the preventive effect of ketamine or esketamine on PPD among women after giving birth through caesarean or vaginal delivery. We extracted PPD occurrence rate, PPD score, pain score and side effects. Finally, a meta-analysis was conducted using RevMan software. Results Twenty-one eligible studies were incorporated in the current systematic review and meta-analysis involving 4,389 pregnant women. Esketamine was the intervention in 14 studies, and ketamine was used in 7 studies. In subgroup analysis, both ketamine and esketamine were significantly effective in reducing the incidence of short-term PPD (ketamine: RR = 0.72, 95% CI [0.56, 0.93], P = 0.01; esketamine: RR = 0.43, P < 0.0001). Esketamine only significantly reduced the incidence of long-term PPD (RR = 0.44, P < 0.00001). Low doses and high doses were effective in reducing the incidence of both short-term (high dose: RR = 0.48, P = 0.0005; low dose: RR = 0.46, P = 0.002) and long-term PPD (high dose: RR = 0.54, P < 0.0001; low dose: RR = 0.61, P = 0.009). Regarding the risk of side effects, patients in the Ketamine/esketamine group showed statistically significant higher rates of developing dizziness (P = 0.0007), blurred vision (P = 0.02), vomiting (P = 0.004) and hallucinations (P = 0,002) than women in the control group. Conclusion Both ketamine and esketamine are effective in lowering the incidence of short-term PPD. On the other hand, only esketamine is effective in reducing the incidence of long-term PPD. It is recommended to use smaller doses for a more tolerable treatment period since doses less than 0.5 mg are significantly effective. Temporary side effects such as dizziness, blurred vision, vomiting and hallucinations were reported. |
| format | Article |
| id | doaj-art-e29f8dc3a9414c43b75d289d6bc5b368 |
| institution | Kabale University |
| issn | 1471-2393 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pregnancy and Childbirth |
| spelling | doaj-art-e29f8dc3a9414c43b75d289d6bc5b3682025-02-09T12:58:58ZengBMCBMC Pregnancy and Childbirth1471-23932025-02-0125113010.1186/s12884-025-07186-yEfficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysisMoaz Yasser Darwish0Abdallah A. Helal1Yousif Ahmed Othman2Manar Alaa Mabrouk3Aya Alrawi4Taha Abd-ElSalam Ashraf5Nada K. Abdelsattar6Fatma Mohammed Sayed7Mohamed Abd-ElGawad8Faculty of Medicine, Fayoum UniversityFaculty of Medicine, Fayoum UniversityFaculty of Medicine, Fayoum UniversityFaculty of Medicine, Fayoum UniversityFaculty of Medicine, Fayoum UniversityFaculty of Medicine, Fayoum UniversityFaculty of Medicine, Fayoum UniversityDepartment of Obstetrics and Gynecology, Faculty of Medicine, Fayoum UniversityFaculty of Medicine, Fayoum UniversityAbstract Background Postpartum depression (PPD) is categorized by the Disorders-Fifth Edition as depression that begins during pregnancy or within the first month after giving birth. Ketamine and esketamine have shown promising results in the treatment of several depressive disorders, which suggests that they may have a role in the prevention of PPD. This systematic review and meta-analysis aim to update evidence about the efficacy and safety of using ketamine and esketamine to reduce PPD incidence. Methods We searched four databases, PubMed, Scopus, Web of Science, and Cochrane, to collect relevant studies. We included studies which investigated the preventive effect of ketamine or esketamine on PPD among women after giving birth through caesarean or vaginal delivery. We extracted PPD occurrence rate, PPD score, pain score and side effects. Finally, a meta-analysis was conducted using RevMan software. Results Twenty-one eligible studies were incorporated in the current systematic review and meta-analysis involving 4,389 pregnant women. Esketamine was the intervention in 14 studies, and ketamine was used in 7 studies. In subgroup analysis, both ketamine and esketamine were significantly effective in reducing the incidence of short-term PPD (ketamine: RR = 0.72, 95% CI [0.56, 0.93], P = 0.01; esketamine: RR = 0.43, P < 0.0001). Esketamine only significantly reduced the incidence of long-term PPD (RR = 0.44, P < 0.00001). Low doses and high doses were effective in reducing the incidence of both short-term (high dose: RR = 0.48, P = 0.0005; low dose: RR = 0.46, P = 0.002) and long-term PPD (high dose: RR = 0.54, P < 0.0001; low dose: RR = 0.61, P = 0.009). Regarding the risk of side effects, patients in the Ketamine/esketamine group showed statistically significant higher rates of developing dizziness (P = 0.0007), blurred vision (P = 0.02), vomiting (P = 0.004) and hallucinations (P = 0,002) than women in the control group. Conclusion Both ketamine and esketamine are effective in lowering the incidence of short-term PPD. On the other hand, only esketamine is effective in reducing the incidence of long-term PPD. It is recommended to use smaller doses for a more tolerable treatment period since doses less than 0.5 mg are significantly effective. Temporary side effects such as dizziness, blurred vision, vomiting and hallucinations were reported.https://doi.org/10.1186/s12884-025-07186-yKetamineEsketaminePostpartum depressionPPD |
| spellingShingle | Moaz Yasser Darwish Abdallah A. Helal Yousif Ahmed Othman Manar Alaa Mabrouk Aya Alrawi Taha Abd-ElSalam Ashraf Nada K. Abdelsattar Fatma Mohammed Sayed Mohamed Abd-ElGawad Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis BMC Pregnancy and Childbirth Ketamine Esketamine Postpartum depression PPD |
| title | Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis |
| title_full | Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis |
| title_short | Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis |
| title_sort | efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression an updated systematic review and meta analysis |
| topic | Ketamine Esketamine Postpartum depression PPD |
| url | https://doi.org/10.1186/s12884-025-07186-y |
| work_keys_str_mv | AT moazyasserdarwish efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT abdallahahelal efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT yousifahmedothman efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT manaralaamabrouk efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT ayaalrawi efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT tahaabdelsalamashraf efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT nadakabdelsattar efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT fatmamohammedsayed efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis AT mohamedabdelgawad efficacyandsafetyofketamineandesketamineinreducingtheincidenceofpostpartumdepressionanupdatedsystematicreviewandmetaanalysis |